3/4
01:10 pm
imnm
Immunome (IMNM) had its price target raised by Craig Hallum from $33.00 to $36.00. They now have a "buy" rating on the stock.
Low
Report
Immunome (IMNM) had its price target raised by Craig Hallum from $33.00 to $36.00. They now have a "buy" rating on the stock.
3/4
12:49 pm
imnm
Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing [Yahoo! Finance]
Low
Report
Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing [Yahoo! Finance]
3/4
09:04 am
imnm
Immunome (IMNM) had its price target lowered by Stephens from $33.00 to $30.00. They now have an "overweight" rating on the stock.
Medium
Report
Immunome (IMNM) had its price target lowered by Stephens from $33.00 to $30.00. They now have an "overweight" rating on the stock.
3/3
04:11 pm
imnm
Immunome Reports Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
Immunome Reports Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]
3/3
04:02 pm
imnm
Immunome Reports Full Year 2025 Financial Results and Provides Business Update
Medium
Report
Immunome Reports Full Year 2025 Financial Results and Provides Business Update
3/2
03:12 am
imnm
Immunome, Inc. (IMNM) Sets Sights on $1B Opportunity amid Pipeline Development [Yahoo! Finance]
Low
Report
Immunome, Inc. (IMNM) Sets Sights on $1B Opportunity amid Pipeline Development [Yahoo! Finance]
2/24
10:46 pm
imnm
Assessing Immunome (IMNM) Valuation After Recent Share Price Pullback [Yahoo! Finance]
Low
Report
Assessing Immunome (IMNM) Valuation After Recent Share Price Pullback [Yahoo! Finance]
2/23
08:22 am
imnm
Immunome to Present at Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
Immunome to Present at Upcoming Investor Conferences [Yahoo! Finance]
2/23
08:00 am
imnm
Immunome to Present at Upcoming Investor Conferences
Low
Report
Immunome to Present at Upcoming Investor Conferences
2/13
11:20 pm
imnm
Immunome CEO Touts Phase 3 Desmoid Win, Near-Term FDA NDA Plan and Early IM-1021 ADC Responses [Yahoo! Finance]
Low
Report
Immunome CEO Touts Phase 3 Desmoid Win, Near-Term FDA NDA Plan and Early IM-1021 ADC Responses [Yahoo! Finance]
2/13
07:02 pm
imnm
Institutional investors in Immunome, Inc. (NASDAQ:IMNM) see US$269m decrease in market cap last week, although long-term gains have benefitted them. [Yahoo! Finance]
Low
Report
Institutional investors in Immunome, Inc. (NASDAQ:IMNM) see US$269m decrease in market cap last week, although long-term gains have benefitted them. [Yahoo! Finance]
2/13
06:29 am
imnm
Immunome (NASDAQ:IMNM) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.
Low
Report
Immunome (NASDAQ:IMNM) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.
2/12
07:17 am
imnm
Immunome (NASDAQ:IMNM) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock.
Medium
Report
Immunome (NASDAQ:IMNM) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock.
2/5
04:00 pm
imnm
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/4
08:17 am
imnm
Immunome to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 [Yahoo! Finance]
Low
Report
Immunome to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 [Yahoo! Finance]
2/4
08:00 am
imnm
Immunome to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Low
Report
Immunome to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
1/24
05:08 am
imnm
Immunome (NASDAQ:IMNM) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Immunome (NASDAQ:IMNM) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/16
03:38 pm
imnm
Immunome (IMNM) Is Up 11.7% After Phase 3 Varegacestat Success - Has The Bull Case Changed? [Yahoo! Finance]
Low
Report
Immunome (IMNM) Is Up 11.7% After Phase 3 Varegacestat Success - Has The Bull Case Changed? [Yahoo! Finance]
1/16
07:34 am
imnm
Assessing Immunome (IMNM) Valuation After Recent Share Price Momentum And Conflicting P/B And DCF Signals [Yahoo! Finance]
Low
Report
Assessing Immunome (IMNM) Valuation After Recent Share Price Momentum And Conflicting P/B And DCF Signals [Yahoo! Finance]
1/15
11:42 am
imnm
Is Immunome, Inc. (IMNM) The Best Booming Stock To Buy Right Now? [Yahoo! Finance]
Medium
Report
Is Immunome, Inc. (IMNM) The Best Booming Stock To Buy Right Now? [Yahoo! Finance]
1/15
09:19 am
imnm
Immunome (NASDAQ:IMNM) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $31.00 price target on the stock.
High
Report
Immunome (NASDAQ:IMNM) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $31.00 price target on the stock.
1/8
04:05 pm
imnm
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/8
08:06 am
imnm
Jim Cramer on Immunome: “If You Want to Speculate on It, Fine” [Yahoo! Finance]
Low
Report
Jim Cramer on Immunome: “If You Want to Speculate on It, Fine” [Yahoo! Finance]
1/6
08:00 am
imnm
Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference
12/20
08:37 am
imnm
Immunome Chairman Acquires 5.8% More Stock [Yahoo! Finance]
Low
Report
Immunome Chairman Acquires 5.8% More Stock [Yahoo! Finance]